{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:23:19Z","timestamp":1793064199133,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109581","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:25:23Z","timestamp":1786663523000},"page":"109581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-7836","authenticated-orcid":false,"given":"Giannis","family":"Mountzios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surein","family":"Arulananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Gumus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Punekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lugini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-763X","authenticated-orcid":false,"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor-Eliade","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-7613","authenticated-orcid":false,"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":false,"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Blackhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Dirnberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8588-5372","authenticated-orcid":false,"given":"Jessie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gauto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-3465","authenticated-orcid":false,"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109581_b0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s41030-023-00229-9","article-title":"Symptoms and experiences with small cell lung cancer: a mixed methods study of patients and caregivers","volume":"9","author":"Bebb","year":"2023","journal-title":"Pulm Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109581_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109581_b0015","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2026.109581_b0020","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109581_b0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109581_b0030","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2026.109581_b0035","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109581_b0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109581_b0045","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fphar.2017.00339","article-title":"The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature","volume":"8","author":"Bennett","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109581_b0050","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/bjc.2013.585","article-title":"Quality of life during chemotherapy in lung cancer patients: results across different treatment lines","volume":"109","author":"Wintner","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109581_b0055","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/S1470-2045(13)70493-5","article-title":"Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials","volume":"15","author":"Zikos","year":"2014","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2026.109581_b0060","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109581_b0065","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109581_b0070","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, Phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109581_b0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","article-title":"International real-world study of DLL3 expression in patients with small cell lung cancer","volume":"147","author":"Rojo","year":"2020","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109581_b0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109581_b0085","unstructured":"Amgen Inc. IMDELLTRA\u2122 (tarlatamab-dlle) for injection, for intravenous use May 2024 [Available from: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Imdelltra\/imdelltra_fpi.pdf."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109581_b0090","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl Cancer Inst."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109581_b0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109581_b0100","unstructured":"The Facit Group. Functional Assessment of Cancer Therapy \u2013 General (FACT-G)."},{"key":"10.1016\/j.lungcan.2026.109581_b0105","unstructured":"EuroQol Research F. EQ-5D-5L."},{"key":"10.1016\/j.lungcan.2026.109581_b0110","article-title":"Derivation of meaningful change thresholds for EORTC QLQ-C30 and QLQ-LC13 in patients with small cell lung cancer","author":"Dirnberger","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.lungcan.2026.109581_b0115","unstructured":"Pfizer Inc. Topotecan. US Prescribing information. December 2019. Accessed July 2026. 2019."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109581_b0120","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1007\/s12325-025-03136-4","article-title":"Patient-reported outcomes for patients with previously treated small cell lung cancer receiving tarlatamab: results from the DeLLphi-301 phase 2 trial","volume":"42","author":"Hummel","year":"2025","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109581_b0125","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109581_b0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2020.09.003","article-title":"Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study","volume":"149","author":"Goldman","year":"2020","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109581_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad002","article-title":"Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials","volume":"7","author":"Lord-Bessen","year":"2023","journal-title":"JNCI Cancer Spectr."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109581_b0140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jnci\/djab177","article-title":"Impact of blinding on patient-reported outcome differences between treatment arms in cancer randomized controlled trials","volume":"114","author":"Efficace","year":"2022","journal-title":"J. Natl Cancer Inst."},{"issue":"20","key":"10.1016\/j.lungcan.2026.109581_b0145","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1002\/cam4.3335","article-title":"Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials","volume":"9","author":"Mouillet","year":"2020","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109581_b0150","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109581_b0155","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(23)00157-2","article-title":"Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures","volume":"24","author":"Pe","year":"2023","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109581_b0160","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109581_b0165","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:54:48Z","timestamp":1789145688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S0169500226006422"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109581","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109581"}}